Antidepressant Medication Use, Weight Gain, and Risk of Type 2 Diabetes: A population-based study by Kivimäki, Mika et al.
Antidepressant Medication Use, Weight
Gain, and Risk of Type 2 Diabetes
A population-based study




G. DAVID BATTY, PHD
1,3
JOHN R. GEDDES, MD, FRCPSYCH
4






JUSSI VAHTERA, MD, PHD
6,7
OBJECTIVE — To examine antidepressant medication use as a risk factor for type 2 diabetes
and weight gain.
RESEARCH DESIGN AND METHODS — A series of nested studies within a prospec-
tive cohort of 151,347 working-aged men and women including 9,197 participants with con-
tinuing antidepressant medication, 224 with severe depression, and 851 with incident type 2
diabetes during a mean follow-up of 4.8 years, as indicated by national health and prescription
registers (the Public Sector study, Finland 1995–2005).
RESULTS — In the ﬁrst analysis, the case subjects were individuals with incident type 2
diabetes compared with matched diabetes-free control subjects. Antidepressant use of 200
deﬁned daily doses was associated with a doubling of diabetes risk in both participants with no
indication of severe depression (odds ratio 1.93 [95% CI 1.48–2.51]) and participants with
severedepression(2.65[1.31–5.39]).Infurtheranalyses,theexposedgroupwasantidepressant
users and the reference group was nonusers matched for depression-related characteristics. The
5-year absolute risk of diabetes was 1.1% for nonusers, 1.7% for individuals treated with
200–399deﬁneddailydosesayear,and2.3%forthosewith400deﬁneddailydoses(Ptrend
0.0001). An average self-reported weight gain, based on repeated surveys, was 1.4 kg (2.5%)
among nonusers and 2.5 kg (4.3%) among users of200 deﬁned daily doses (Ptrend  0.0001).
Separate analyses for tricyclic antidepressants and selective serotonin reuptake inhibitors repli-
cated these ﬁndings.
CONCLUSIONS — In these data, continuing use of antidepressant medication was associ-
atedwithanincreasedrelativeriskoftype2diabetes,althoughtheelevationinabsoluteriskwas
modest.
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A
ntidepressantsaresomeofthemost
commonly prescribed drugs world-
wide (1,2). Although their efﬁcacy
in the acute-phase therapy of depression
might be lower than initially thought (3–
6), there is substantial evidence that con-
tinuation of therapy reduces the risk of
relapse in patients who initially respond
to therapy (7,8). Long-term antidepres-
sant therapy is routinely recommended
for recurrent unipolar depression (7,8).
Recent studies have raised the possi-
bility that continuing antidepressant use
might increase the risk of type 2 diabetes,
as an unwanted side effect (9–13). For
several reasons, this hypothesis warrants
further scrutiny. First, it is based on a
small number of epidemiological studies
withlimitedinformationonconsumption
of antidepressants (type, dose, and dura-
tion). Second, owing to the absence of
direct monitoring for diabetes risk and
short follow-up periods (typically
months), randomized controlled trials on
antidepressants have, thus far, been un-
able to robustly examine the long-term
antidepressant-diabetes association
(6,14). Third, if antidepressant use does
indeed inﬂuence the risk of diabetes, the
mechanisms responsible, such as weight
gain,amajorriskfactorfordiabetes,need
to be ascertained.
Study members in the present epide-
miological cohort have been linked to
complete national pharmacy records
from which the daily dose of antidepres-
sant medication, based on World Health
Organization (WHO) deﬁnitions of aver-
age maintenance dose (15), can be cap-
tured.Inaddition,participants’responses
tosurveysatstudybaselineandfollow-up
enable determining change in self-
reported weight over time. Accordingly,
the aim of this study is to examine
whether exposure to antidepressant med-
ication use is associated with type 2 dia-
betes risk in a large population of men
and women (Aim 1) and whether there is
a difference in weight gain among antide-
pressant users compared with equally de-
pressed individuals who are not treated
withantidepressants(Aim2).Becausethe
beneﬁts of antidepressant therapy may be
substantial only for patients with severe
depression (3), we also examined the an-
tidepressant-diabetes association sepa-
ratelyinthisgroupandamongthosewith
mild or moderate symptoms.
RESEARCH DESIGN AND
METHODS— We performed three
interrelated nested studies in an occupa-
tional cohort of 151,347 employees in
Finland (16). The eligible population of
151,347 participants was linked to na-
tional health and prescription registers
through unique personal identiﬁcation
codes assigned to all citizens in Finland.
For all participants in the eligible popula-
tion, the linkage to registers was 100%
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tion during the follow-up.
Study 1 examined differences in anti-
depressant medication use between 851
individuals with incident type 2 diabe-
tes and their 4,234 individually matched
diabetes-free control subjects with com-
plete records of severe depression and
prescribedantidepressantuseoveraﬁxed
period of 4 years before the diagnosis of
type 2 diabetes between 1 January 2001
and 31 December 2005. The randomly
selected control subjects were drawn in a
5:1 ratio for each diabetes case subject,
matching individually for age-group, sex,
socioeconomic position, type of employ-
ment contract, type of employer, and geo-
graphic area. For a ﬂow chart depicting
sampleselection,seesupplementaryeFig.1
(available in an online appendix at http://
care.diabetesjournals.org/cgi/content/full/
dc10-1187/DC1).
Because we were unable to estimate
absolute risk of diabetes associated with
antidepressant use with the retrospective
case-control design in study 1, we under-
took study 2. It is a prospective follow-up
of all 9,197 identiﬁed continuing antide-
pressant users (200 deﬁned daily doses
a year, i.e., a treatment lasting 6
months). For comparison, we selected
nonusercontrolsubjects(n45,658)us-
ing the same record-based matching
method as in study 1. A minimum fol-
low-up for incident diabetes was set at 12
months (supplementary eFig. 2, available
in an online appendix).
Study 3 is a prospective follow-up of
self-reported weight change between
baseline survey in 2000–2002 and fol-
low-up survey in 2004–2005 for all
identiﬁed1,404antidepressantuserspar-
ticipating in the surveys and their 4,133
matched control subjects (nonusers)
(supplementary eFig. 3, available in an
online appendix). We used propensity-
based matching (a quasi-experimental
“correction strategy”) to select for each
case subject one to three control subjects
who had the same probability as the case
subjects for receiving treatment with re-
spect to depression status and other de-
pression-related covariates, discarding
unmatched individuals. Antidepressant
users were matched for the same charac-
teristics as those used in studies 1 and 2
and also for diagnosed depression, isch-
emic heart disease, stroke, cancer, use of
pain killers, hypnotics, or anxiolytics,
self-rated psychological distress, sleeping
problems, and anxiety to the closest con-
trol subject whose propensity score dif-
fered by 0.01.
Measurements
Full details of the measurements and sta-
tistical analysis are provided in the sup-
plementary material (available in an
online appendix). In brief, antidepressant
use for each year of the observation was
derived from the nationwide Drug Pre-
scription Register. The data contained in-
formation on the day of purchase; dose,
stated as the international standard de-
ﬁned daily dose; and medication classi-
ﬁed according to the WHO Anatomical
Therapeutic Chemical (ATC) classiﬁca-
tion (15). We determined the consump-
tion of antidepressants on the basis of
deﬁneddailydosesforthepurchasesofall
antidepressants (ATC code N06A) and
the following classes: tricyclic antidepres-
sants (ATC code N06AA), selective sero-
tonin reuptake inhibitors (SSRIs) (ATC
code N06AB) and other antidepressants
(ATC codes N06AF, N06AG, and
N06AX; for speciﬁc drugs, see supple-
mentary eTable 4, available in an online
appendix).
Severe depression was deﬁned by
psychiatric hospital admission (the Na-
tional Hospital Discharge Register),
record of long-term psychotherapy
granted by the Social Insurance Institu-
tion (minimum 1 year), or record of work
disability 90 days (the Social Insurance
Institution of Finland and the Finnish
Centre for Pensions registers) for ICD-10
diagnostic codes F32–F34.
Participants were deﬁned as incident
type 2 diabetes case subjects the ﬁrst time
they were listed in the Central Drug Reg-
ister as eligible for diabetes treatment due
to type 2 diabetes (ICD-10 code E11) be-
tween 1 January 2001 and 31 December
2005. The Central Drug Register, main-
tainedbytheSocialInsuranceInstitution,
lists all such patients with physician-
documented evidence of fasting whole
blood glucose 7.0 mmol/l (or fasting
plasma glucose 8.0 mmol/l) and symp-
toms of diabetes, such as polyuria, poly-
dipsia, and glucosuria. If symptoms are
notpresent,evidenceofasecondelevated
blood glucose level 7.0 mmol/l is re-
quired. To exclude prevalent diabetes
(i.e., diabetes diagnosed before 31 Janu-
ary 2001), we also linked the data to the
Finnish Hospital Discharge Register that
lists all discharged hospital patients with
information on dates of admission and
dischargesince1987andtotheDrugPre-
scription Register (Social Insurance Insti-
tution) that includes all prescriptions for
insulinmedications,drugstolowerblood
glucose, and other drugs for diabetes in
Finland nationwide since 1994, accord-
ing to the WHO ATC classiﬁcation.
Statistical analysis
Allstatisticalanalyseswereperformedus-
ing the SAS 9.2 (SAS Institute, Cary, NC).
Statistical signiﬁcance was inferred at a
two-tailed P  0.05. There were no clear
differences in the associations of antide-
pressant use with diabetes or weight gain
between men and women (P for all sex
interactions  0.26), so the data were
pooled and sex-adjusted. The cohort was
raciallyhomogeneous(whiteEuropeans).
RESULTS
Relative risk of incident type 2
diabetes (study 1)
Table1showsthatantidepressantusewas
associated with increased risk of incident
diabetes in both participants with no in-
dication of severe depression (odds ratio
[OR] 1.93 [95% CI 1.48–2.51] (compar-
ison A in Table 1) and participants with
severe depression (2.65 [1.31–5.39]
(comparison C in Table 1). In contrast,
there was a weaker association between
severe depression and incident diabetes
among both nonusers of antidepressants
(1.20 [0.64–2.25]) (comparison A in Ta-
ble 1) and antidepressant users (1.65
[1.09–2.48]) (comparison B in Table 1).
This pattern of results was robust to ad-
justment for baseline chronic diseases,
such as prevalent hypertension, coronary
heart disease, stroke, and cancer.
Analyses combining severely depres-
sive and less severely depressive groups
replicated these ﬁndings (ﬁgures not pro-
vided in Table 1). Thus, participants with
an exposure to 200 deﬁned daily doses
ofantidepressants(n490)hadanORof
2.29[95%CI1.85–2.83]timeshigherfor
diabetes than those with antidepressant
use 200 deﬁned daily doses (n 
4,595). Severe depression (224 case sub-
jectsand4,861noncasesubjects)wasalso
associatedwithanincreasedriskoftype2
diabetes (2.33 [1.74–3.12]). In a mutu-
ally adjusted model, the excess diabetes
risk associated with antidepressant use
was reduced only by 21.0%, whereas the
excessdiabetesriskassociatedwithsevere
depression was attenuated by 68.4%.
In a sensitivity analysis, the depres-
sion-diabetes association was substan-
tially attenuated after adjustment for
antidepressant use irrespective of the
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sion: hospitalization records, work dis-
ability records, or records of long-term
psychotherapy (supplementary eTable 2,
availableinanonlineappendix).Further-
more, results of tests for synergistic inter-
action(synergyindex1.94[95%CI0.82–
4.55])andmultiplicativeinteraction(P
0.41) were both negative, suggesting
that the excess risk of incident diabetes
associated with antidepressant use and
depression was not additive or multipli-
cative. In further sensitivity analyses, the
association between antidepressant use
and incident diabetes was seen irrespec-
tive of whether 200 deﬁned daily doses
(an exposure equivalent to 6 months of
continuing antidepressant use during the
4-year period) or 400 deﬁned daily
doses (representing 1 year of continu-
ing use) were used to deﬁne antidepres-
sant medication use (supplementary
eTable3, available in an online appendix)
and for both tricyclic antidepressants and
SSRIs (supplementary eTables 4 and 5,
available in an online appendix).
Absolute risk of diabetes (study 2)
A prospective analysis with 9,197 antide-
pressant users (200 deﬁned daily doses
within 1 year) and their 45,658 matched
nontreatedcontrolsubjectsreplicatedthe
excess risk associated with long-term an-
tidepressant use (supplementary eTable
6, available in an online appendix). For 5
years, the absolute risk of incident diabe-
tes was 1.8% for antidepressant users and
1.1% for matched nonusers (calculated
based on a mean follow-up of 4.75 years
[range 1–11 years]). The corresponding




2,319) was 2.3%. The relative risk esti-
mates(hazardratios)forincidentdiabetes
associated with antidepressant use of
200–399 deﬁned daily doses and 400
deﬁned daily doses compared with no
use were 1.53 (95% CI 1.25–1.87) and
2.00 (1.51–2.66), respectively. P 
0.0001foratrendacrossantidepressant
use categories supports a “dose-
response” association between antide-
pressant use and incident type 2
diabetes. Figure 1 shows that there was
separation of the survival curves be-
tween antidepressant users (200 de-
ﬁned daily doses within 1 year) and
nonusers across the entire follow-up
period.
Figure 1—Cumulative hazard function for incident type 2 diabetes for participants with long-
term antidepressant medication use (200 deﬁned daily doses 1 year) and their individually
matched control subjects with no record of antidepressant use.
Table 1—Severe depression and use of antidepressant medication during the 4 years preceding diabetes diagnosis among participants with






(no. incident diabetes cases)
ORs (95% CI) for incident diabetes
Comparison A Comparison B Comparison C
No No 4,530 (696) 1 (reference) 0.52 (0.40–0.67) 0.84 (0.44–1.57)
No Yes 331 (85) 1.93 (1.48–2.51) 1 (reference) 1.61 (0.82–3.16)
Yes No 65 (12) 1.20 (0.64–2.25) 0.62 (0.32–1.22) 1 (reference)
Yes Yes 159 (58) 3.17 (2.27–4.45) 1.65 (1.09–2.48) 2.65 (1.31–5.39)
Additional adjustment for prevalent physical disease†
No No 4,530 (696) 1 (reference) 0.60 (0.45–0.79) 0.95 (0.49–1.84)
No Yes 331 (85) 1.68 (1.27–2.21) 1 (reference) 1.59 (0.79–3.22)
Yes No 65 (12) 1.05 (0.55–2.04) 0.63 (0.31–1.27) 1 (reference)
Yes Yes 159 (58) 2.76 (1.93–3.94) 1.64 (1.06–2.54) 2.61 (1.25–5.49)
Resultsarebasedonconditionallogisticregressionanalysis.*“Yes”referstoaminimumuseof200deﬁneddailydosesofantidepressantsand“No”toauseof0–199
deﬁned daily doses during 4 years. †Hypertension, coronary heart disease, cerebrovascular disease, and cancer. Prevalence of cardiovascular disease 4 years before
the diabetes diagnosis was higher among diabetic case subjects than among control subjects (hypertension 28.0 vs. 9.3%, P  0.0001; coronary heart disease 3.2
vs. 1.4%, P  0.0002). There was no difference in cerebrovascular disease (0.7 vs. 0.8, P  0.88) or cancer prevalence (2.7 vs. 2.4%, P  0.61) between the groups.
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Table 2 shows that antidepressant users
(case subjects) were 0.9 kg heavier at
baseline and 2.1 kg heavier at follow-up,
an average of 3.7 years later (range 2–5
years), compared with equally depressed
control subjects with no record of antide-
pressant use (for baseline characteristics
of case and control subjects, see supple-
mentary eTable 7, available in an online
appendix). Mean weight gain was 2.5 kg
(4.3% in 4 years) in the antidepressant
treatment case subjects but only 1.4 kg
(2.5%) in control subjects with no such
treatment. The 4-year proportional
changeinweightbetweenthesurveyswas
essentially the same for the case subjects
across the major types of antidepressant
medications: 4.6% for SSRI users and
4.7% for tricyclic antidepressant users.
For the incident users of any antide-
pressants, users of SSRIs, and users of tri-
cyclic antidepressants, the proportional
change in weight (with adjustment for
weight before antidepressant treatment)
was 4.5, 4.7, and 7.5%, respectively,
whereas among the nonusers, these pro-
portions ranged between 1.5 and 2.4%
(supplementary eTable 8, available in an
online appendix). When 400 deﬁned
daily doses was used to deﬁne long-term
antidepressantuse,meanweightgainwas
greater: 2.9 kg (4.9%) among the users
and 1.4 kg (2.5%) among the nonusers.
Because of the small numbers of inci-
dent diabetes case subjects between the
baseline and follow-up surveys (n  32)
among those who responded to both sur-
veys, no meaningful analysis of the asso-
ciation between antidepressant use and
diabetes risk was possible.
CONCLUSIONS— Analyses of data
drawn from a cohort of 150,000
adults revealed a series of important re-
sults. First, antidepressant medication
use, as indicated by completed pre-
scriptions exceeding 200 deﬁned daily
doses,wasassociatedwithadoublingof
the risk of diagnosed type 2 diabetes,
irrespectiveofarecordofseveredepres-
sion.Theexcessriskassociatedwithan-
tidepressants was observable for both
SSRIsandtricyclicantidepressants.Sec-
ond, in absolute terms, the 5-year risk
of diagnosed diabetes increased in a
dose-response fashion, depending on
the level of exposure to antidepressant
medication: 1.1% in nonusers, 1.7%
among those treated with 200–399
daily deﬁned doses 1 year, and 2.3%
among those using 400 doses. Third,
supportingbiologicalplausibilityofthis
association, weight gain was more rapid
among long-term antidepressant users
than in nonusers matched for depres-
sion-related characteristics.
Our ﬁndings add to the existing evi-
dencefromrecentstudies.Intherandom-
ized Diabetes Prevention Program of
prediabetic individuals, use of antide-
pressants at baseline was associated with
an increased risk of type 2 diabetes at fol-
low-up, whereas self-reported depressive
symptoms at baseline were not predictive
of subsequent diabetes risk (9). An anal-
ysis of medical records of depressive pa-
tients from the U.K. General Practice
Research Database found that long-term
use of antidepressants with high or mod-
erate daily doses was associated with in-
creased risk of diabetes, but treatment
withlowerdailydoseswasnot(10).Inthe
present study, the number of antidepres-
sant users was 6 times higher than that in
these two studies together, and we tar-
geted a nonclinical occupational cohort
including groups that were not covered
by those studies, also took into account
dose and duration of antidepressant use
Table 2—Weight gain in antidepressant users and propensity score: matched nonusers
Antidepressant users Control P value*
Any antidepressant
n 1,404 4,133
Weight at baseline (kg) 70.5 (69.8–71.2) 69.6 (69.2–70.0) 0.02
Weight at follow-up (kg)† 73.1 (72.4–73.8) 71.0 (70.6–71.4) 0.0001
Weight change between baseline and follow-up (kg)† 2.54 (2.28–2.80) 1.37 (1.22–1.52) 0.0001
Relative change in weight (%)‡ 4.25 (3.81–4.69) 2.48 (2.22–2.74) 0.0001
SSRI
n 1,210 3,563
Weight at baseline (kg) 70.6 (69.8–71.3) 69.4 (69.0–69.9) 0.007
Weight at follow-up (kg)† 73.4 (72.6–74.2) 70.8 (70.3–71.3) 0.0001
Weight change between baseline and follow-up (kg)† 2.79 (2.52–3.07) 1.38 (1.22–1.54) 0.0001
Relative change in weight (%)‡ 4.63 (4.17–5.09) 2.44 (2.16–2.71) 0.0001
Tricyclic antidepressants
n 140 402
Weight at baseline (kg) 72.6 (70.3–74.9) 70.1 (68.7–71.4) 0.06
Weight at follow-up (kg)† 75.3 (72.9–77.6) 71.4 (70.0–72.8) 0.005
Weight change between baseline and follow-up (kg)† 2.70 (1.88–3.52) 1.29 (0.81–1.77) 0.004
Relative change in weight (%)‡ 4.24 (2.91–5.57) 2.34 (1.56–3.12) 0.02
Other antidepressants
n 422 1,237
Weight at baseline (kg) 70.6 (69.3–71.9) 71.9 (71.1–72.6) 0.08
Weight at follow-up (kg)† 73.0 (71.6–74.3) 73.5 (72.7–74.3) 0.49
Weight change between baseline and follow-up (kg)† 2.42 (1.93–2.91) 1.65 (1.36–1.94) 0.007
Relative change in weight (%)‡ 4.15 (3.37–4.93) 2.69 (2.23–3.15) 0.002
Data are means (95% CI) unless otherwise indicated. Subjects were matched for depression and 14 related factors. Antidepressant use refers to a minimum use of
200 deﬁned daily doses of antidepressants during 4 years. *Multilevel analysis of variance. †Mean  SD follow-up 3.7  0.9 years. ‡Calculated for 4 years.
Antidepressants, weight gain, and diabetes
2614 DIABETES CARE, VOLUME 33, NUMBER 12, DECEMBER 2010 care.diabetesjournals.orgas well as baseline status of severe depres-
sion, and demonstrated a plausible medi-
ating mechanism.
Other studies in the ﬁeld have re-
ported inconsistent ﬁndings. A Norwe-
gian cross-sectional health survey (11), a
study of spontaneous reports listed in
the WHO Adverse Drug Reaction Data-
base (12), and an analysis of data from
one province in Canada (13) all found
support for an association between anti-
depressantuseanddiabetes.Inacommu-
nity sample of adults aged 55 years,
treatment with antidepressants was not
associated with an increased risk of dia-
betes, but the study lacked adequate sta-
tistical power because the number of
antidepressant users who developed dia-
betes was only four (17). Analyses using
prescription data from the PHARMO da-
tabase from the Netherlands did not ﬁnd
an increased risk of diabetes among anti-
depressant users (18). However, that
studydidnotconsiderthedurationorthe
dose of antidepressant treatment. Our
ﬁndings and other studies (10) suggest
that inclusion of short-term/low-dose
treatmentsinthedeﬁnitionofantidepres-
sant use is likely to dilute the association.
In the present study, exposure to 200
deﬁneddailydosesofantidepressantswas
not associated with diabetes risk.
Weight gain, both in relative and ab-
solute terms, was greater among antide-
pressant users than among their control
subjects matched for depression status
using recorded and self-reported infor-
mationondepressionandrelatedtraits.A
previous trajectory analysis of repeat BMI
measurements found on average a 0.03
unit faster annual increase in BMI among
individuals who later developed type 2
diabetes compared with those who re-
mained disease-free (19). This translates
to0.1kgexcessweightgainperyearfor
incident diabetes case subjects. With use
of that metric, our ﬁndings suggest that
antidepressant medication use is related
to 0.3 kg excess yearly weight gain, a
change clearly large enough to contribute
todiabetesrisk.Ourﬁndingsareinagree-
ment with previous studies conﬁrming
that tricyclic antidepressants may induce
weight gain and promote hyperglycemia
(20,21) and showing that SSRI use, de-
spite being related to stable weight or
even weight loss in the short term, is as-
sociated with an increased risk of weight
gain in the longer term (22).
In the weight gain study reported
herein, we undertook a sensitivity analy-
sis based on a subgroup of incident anti-
depressant medication users who started
treatment between baseline and fol-
low-up weight measurements, excluding
all prevalent antidepressant users. This
exclusion affected little estimated signiﬁ-
cant weight gain associated with SSRIs
but showed even a greater weight gain in
relation to tricyclic antidepressant treat-
ment.Becauseweightgainisarecognized
side effect of tricyclic antidepressants, the
main analysis may include an underrep-
resentation of patients who did not toler-
ate antidepressant treatment well (the
depletion of susceptibility bias), contrib-
uting to an underestimation of the weight
gain associated with tricyclic antidepres-
sant treatment.
Strengths and limitations
Information on the daily dose of antide-
pressant medication, based on WHO def-
initions of average maintenance dose, is
an advantage because it enabled determi-
nation of the level of exposure to these
drugs. Use of records of completed anti-
depressant prescriptions is also a speciﬁc
strength, because previous studies have
typically relied on information on pre-
scriptions irrespective of whether the pa-
tient actually ﬁlled them. Our data on
antidepressants, being based on physi-
cian-prescribed medication that was then
purchased by the user from a pharmacy,
are likely to be more accurate, although
we cannot ascertain the extent to which
the medication purchased was actually
taken. In this study, comprehensive
records on medications and diagnoses of
depression and diabetes from national
registers unusually covered the entire co-
hort during the entire follow-up period.
Thus, biases related to sample attrition
were avoided.
Several limitations to this study are
noteworthy. First, the assessment of type
2 diabetes and depression with records
from national health registers does not
capture nondiagnosed or nontreated dia-
betes or depression, introducing a source
of misclassiﬁcation. However, an associa-
tion of antidepressant use and incident
diabetes, similar to that found in the
present study, has previously been con-
ﬁrmed in a study with glucose-based as-
sessment of incident type 2 diabetes (9),
which will capture case subjects with
nondiagnosed and nontreated diabetes.
Second, we assessed weight change
using self-reports. Although self-reported
weights are correlated with objective
weight measurements, there are errors in
self-reports that are systematic instead of
random, reﬂecting both roundings to the
nearest point of heaping and a tendency
toreportweightsclosertoidealweight.In
the present study, the weight change cal-
culatedbydeductingself-reportedweight
at follow-up from that at baseline may
therefore have, if anything, underesti-
mated large weight changes. The inﬂu-
ence of antidepressant use on the
accuracy of self-reporting is not known;
such impacts could potentially introduce
some bias to our results.
Third, other mechanisms beyond
weight gain, such as the hyperglycemic
effects of noradrenergic activity of antide-
pressants,mayhavearoleintheincreased
diabetes risk associated with antidepres-
sants. Further research is therefore
needed to examine the entire pathway
from antidepressant use to subsequent
physical and biochemical changes, in-
cluding weight gain and the onset of type
2diabetes.Giventhatdiabetogeniceffects
are likely to vary depending on a drug’s
chemical substance, antidepressant-
speciﬁc analyses, beyond those of SSRIs
and tricyclic medication, would be im-
portant and should cover, for example,
the increasingly popular serotonin-
norepinephrine reuptake inhibitors.
Fourth, the possibility of residual or
unmeasured confounding cannot be ex-
cluded in epidemiological studies such as
ours. The fact that the association be-
tween antidepressant use and diabetes
wassimilarinseverelydepressivepatients
and the remaining study members sug-
gests that the observed association was
not driven by confounding factors
strongly related to depression. Likewise,
the association of antidepressant use and
weightgainwasrobusttomatchingfor16
depression-related characteristics, such
as GHQ-12 caseness, a correlate of clini-
cal depression (23).
Fifth, observational data cannot
prove causality. We therefore recom-
mend conﬁrmatory studies, such as
postintervention follow-ups for existing
antidepressant trials for assessment of di-
abetes risk in randomized data.
Implications
Potential diabetes risk is currently not
takenintoconsiderationinclinicalguide-
lines for treating depression (8,24). We
observedasubstantiallyincreasedrelative
and modestly increased absolute risk of
type 2 diabetes associated with continu-
ing antidepressant medication use. If this
risk reﬂects a causal effect, then it should
be incorporated into clinical decision
Kivima ¨ki and Associates
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 12, DECEMBER 2010 2615making in recurrent depression because
diabetes is a serious disease with poten-
tially fatal complications.
Acknowledgments— M.K. and J.V. are sup-
portedbytheAcademyofFinland.M.K.isalso
supported by a BUPA Foundation Specialist
Research Grant, U.K., the National Institutes
of Health National Heart, Lung, and Blood In-
stitute (grant R01-HL-036310) and the Na-
tional Institute on Aging (grant R01-AG-
034454). G.D.B is a Wellcome Trust Research
Fellow, U.K. The Medical Research Council
(MRC) Social and Public Health Sciences Unit
receives funding from the U.K. MRC and the
Chief Scientist Ofﬁce at the Scottish Govern-
mentHealthDirectorates.TheCentreforCog-
nitive Ageing and Cognitive Epidemiology is
supported by the Biotechnology and Biologi-
cal Sciences Research Council, the Engineer-
ing and Physical Sciences Research Council,
the Economic and Social Research Council,
the MRC, and the University of Edinburgh as
part of the cross-council Lifelong Health and
Wellbeing initiative.
No potential conﬂicts of interest relevant to
this article were reported.
The funders had no role in study design,
data collection and analysis, decision to pub-
lish, or preparation of the article.
M.K. formulated the initial hypotheses, de-
signedthestudy,contributedtointerpretation
of the data, wrote the manuscript, and re-
viewed/edited the manuscript. M.H.,
G.D.B. J.R.G., A.G.T. and M.V. designed the
study, contributed to interpretation of the
data, and reviewed/edited the manuscript. J.P.
designed the study, contributed to interpreta-
tion of the data, analyzed data, and reviewed/
edited the manuscript. J.V. formulated the
initialhypothesis,designedthestudy,contrib-
uted to interpretation of the data, and re-
viewed/edited the manuscript.
References
1. Olfson M, Marcus SC. National pat-
terns in antidepressant medication treat-
ment. Arch Gen Psychiatry 2009;66:
848–856
2. Reid S, Barbui C. Long term treatment of
depression with selective serotonin re-
uptake inhibitors and newer antidepres-
sants. BMJ 2010;340:c1468
3. Fournier JC, DeRubeis RJ, Hollon SD,
Dimidjian S, Amsterdam JD, Shelton RC,
FawcettJ.Antidepressantdrugeffectsand
depression severity: a patient-level meta-
analysis. JAMA 2010;303:47–53
4. Turner EH, Rosenthal R. Efﬁcacy of anti-
depressants. BMJ 2008;336:516–517
5. Turner EH, Matthews AM, Linardatos E,
Tell RA, Rosenthal R. Selective publica-
tion of antidepressant trials and its inﬂu-
ence on apparent efﬁcacy. N Engl J Med
2008;358:252–260
6. Kirsch I, Deacon BJ, Huedo-Medina TB,
Scoboria A, Moore TJ, Johnson BT. Initial
severity and antidepressant beneﬁts: a
meta-analysis of data submitted to the
Food and Drug Administration. PLoS
Med 2008;5:e45
7. Geddes JR, Carney SM, Davies C, Fu-
rukawaTA,KupferDJ,FrankE,Goodwin
GM. Relapse prevention with antidepres-
sant drug treatment in depressive disor-
ders: a systematic review. Lancet 2003;
361:653–661
8. National Institute for Clinical Excellence
(NHS National Institute for Clinical Ex-
cellence). Depression (amended): Man-
agement of depression in primary and
secondary care—NICE guidance [article
online], 2007. Available from http://
www.nice.org.uk/CG023. Accessed Oc-
tober 10, 2010
9. Rubin RR, Ma Y, Marrero DG, Peyrot M,
Barrett-Connor EL, Kahn SE, Haffner SM,
PriceDW,KnowlerWC,DiabetesPreven-
tion Program Research Group. Elevated
depression symptoms, antidepressant
medicine use, and risk of developing dia-
betes during the diabetes prevention pro-
gram. Diabetes Care 2008;31:420–426
10. AndersohnF,SchadeR,SuissaS,GarbeE.
Long-term use of antidepressants for de-
pressive disorders and the risk of diabetes
mellitus. Am J Psychiatry 2009;166:591–
598
11. Raeder MB, Bjelland I, Emil Vollset S,
Steen VM. Obesity, dyslipidemia, and di-
abetes with selective serotonin reuptake
inhibitors: the Hordaland Health Study.
J Clin Psychiatry 2006;67:1974–1982
12. DerijksHJ,MeyboomRH,HeerdinkER,De
Koning FH, Janknegt R, Lindquist M, Eg-
berts AC. The association between antide-
pressant use and disturbances in glucose
homeostasis: evidence from spontaneous
reports. Eur J Clin Pharmacol 2008;
64:531–538
13. Brown LC, Majumdar SR, Johnson JA.
Typeofantidepressanttherapyandriskof
type2diabetesinpeoplewithdepression.
Diabetes Res Clin Pract 2008;79:61–67
14. McIntyre RS, Soczynska JK, Konarski
JZ, Kennedy SH. The effect of antide-
pressants on glucose homeostasis and
insulin sensitivity: synthesis and mech-
anisms. Expert Opin Drug Saf 2006;5:
157–168
15. WHO Collaborating Centre for Drug Sta-
tistics Methodology. Guidelines for ATC
classiﬁcation and DDD assignment [arti-
cle online], 2004. Available from http://
www.whocc.no/atc_ddd_publications/
guidelines/. Accessed October 10, 2010
16. Kivima ¨ki M, Taba ´k AG, Lawlor DA, Batty
GD, Singh-Manoux A, Jokela M, Virtanen
M, Salo P, Oksanen T, Pentti J, Witte DR,
Vahtera J. Antidepressant use before and
after the diagnosis of type 2 diabetes: a
longitudinal modeling study. Diabetes
Care 2010;33:1471–1476
17. Campayo A, de Jonge P, Roy JF, Saz P, de
la Ca ´mara C, Quintanilla MA, Marcos G,
Santaba ´rbara J, Lobo A, ZARADEMP
Project. Depressive disorder and incident
diabetes mellitus: the effect of character-
istics of depression. Am J Psychiatry
2010;167:580–588
18. Knol MJ, Geerlings MI, Egberts AC,
Gorter KJ, Grobbee DE, Heerdink ER. No
increased incidence of diabetes in antide-
pressant users. Int Clin Psychopharmacol
2007;22:382–386
19. Brunner EJ, Shipley MJ, Witte DR, Kivi-
ma ¨ki M, Tabak AG. BMI trajectories and
diabetes in the Whitehall II study. Paper
presented at the 45th Annual Meeting of
the European Diabetes Epidemiology
Group, 15–18 May 2010, Porto Heli,
Greece
20. Lustman PJ, Grifﬁth LS, Clouse RE,
Freedland KE, Eisen SA, Rubin EH, Car-
neyRM,McGillJB.Effectsofnortriptyline
on depression and glycemic control in di-
abetes:resultsofadouble-blind,placebo-
controlled trial. Psychosom Med 1997;
59:241–250
21. Aronne LJ, Segal KR. Weight gain in the
treatment of mood disorders. J Clin Psy-
chiatry 2003;64(Suppl 8):22–29
22. Demyttenaere K, Jaspers L. Review: Bu-
propion and SSRI-induced side effects.
J Psychopharmacol 2008;22:792–804
23. Goldberg DP. Detecting Psychiatric Illness
by Questionnaire. Maudsley Monograph
21. London, Oxford University Press,
1972
24. Karasu TB, Gelenberg A, Merriam A,
Wang P. Practice Guideline for the Treat-
ment of Patients with Major Depressive Dis-
order. 2nd ed. Arlington, VA, American
Psychiatric Publishing, 2000
Antidepressants, weight gain, and diabetes
2616 DIABETES CARE, VOLUME 33, NUMBER 12, DECEMBER 2010 care.diabetesjournals.org